IllnessBreast cancer / therapy with PARP inhibitors
Summary
2 single gene sequence analyses (BRCA1, BRCA2 genes) because of breast cancer in order to decide on the suitability of PARP-inhibitor therapy
- (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
- Gewebeprobe
NGS +
Sanger
Gene panel
Informations about the disease
Mutations in the BRCA1/2 genes are associated with an increased risk of familial breast or ovarian cancer, but also with a better response to therapy in breast cancer patients. The randomized Phase 3 study OlympiAD evaluated the efficacy and safety of olaparib monotherapy versus chemotherapy of choice in patients with metastatic breast cancer and germline mutations in the BRCA1 or BRCA2 genes. Progression-free survival was increased from 4.2 months (chemotherapy) to 7 months (olaparib) (2). The PARP inhibitor olaparib is approved for the treatment of advanced or metastatic HER2-negative BRCA mutant breast cancer that has previously responded sensitively to platinum-based chemotherapy (1).
References: (1) https://www.dgho.de/aktuelles/news/newsarchiv/2019/olaparib-beim-brcamut-mammakarzinom
(2) https://www.nejm.org/doi/full/10.1056/nejmoa1706450
- Alias: Mamma-Ca (Behandlung mit PARP-Inhibitoren)
- Alias: Mamma-Karzinom (BRCA1, BRCA2); Therapie
- Alias: Olaparib-Therapie
- Breast cancer (BRCA1, BRCA2) - Olaparib therapy
- AD
- Mult
- No OMIM-Ps linked
Bioinformatics and clinical interpretation
No text defined